Details of the Drug

General Information of Drug (ID: DMGN4BY)

Drug Name
Flurbiprofen
Synonyms
Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1′ -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Approved [1]
Rheumatoid arthritis FA20 Approved [2]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 244.26
Logarithm of the Partition Coefficient (xlogp) 4.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
92% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
2.9% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.7 hours [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 17.545 micromolar/kg/day [6]
Vd
The volume of distribution (Vd) of drug is 14 L []
Chemical Identifiers
Formula
C15H13FO2
IUPAC Name
2-(3-fluoro-4-phenylphenyl)propanoic acid
Canonical SMILES
CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
InChI
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
InChIKey
SYTBZMRGLBWNTM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3394
ChEBI ID
CHEBI:5130
CAS Number
5104-49-4
DrugBank ID
DB00712
TTD ID
D0A1PX
VARIDT ID
DR00587
INTEDE ID
DR0731
ACDINA ID
D00287
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Modulator [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [8]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [9]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Gene/Protein Processing [11]
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [12]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [13]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [13]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [13]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Protein Interaction/Cellular Processes [14]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [15]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Biotransformations [16]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Gene/Protein Processing [17]
ELAV-like protein 1 (ELAVL1) OTY55PLY ELAV1_HUMAN Gene/Protein Processing [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Osteoarthritis
ICD Disease Classification FA00-FA05
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.10E-01 -5.91E-02 -3.60E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Flurbiprofen
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Sulfasalazine. Rheumatoid arthritis [FA20] [19]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Dexamethasone. Rheumatoid arthritis [FA20] [20]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and Leflunomide. Rheumatoid arthritis [FA20] [21]
Coadministration of a Drug Treating the Disease Different from Flurbiprofen (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [22]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Repaglinide. Acute diabete complication [5A2Y] [23]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Glibenclamide. Acute diabete complication [5A2Y] [23]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Tolazamide. Acute diabete complication [5A2Y] [23]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Nateglinide. Acute diabete complication [5A2Y] [23]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Glipizide. Acute diabete complication [5A2Y] [23]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Flurbiprofen and Inotersen. Amyloidosis [5D00] [24]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Flurbiprofen and Cilostazol. Arterial occlusive disease [BD40] [25]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Budesonide. Asthma [CA23] [20]
Ofloxacin DM0VQN3 Moderate Additive CNS depression effects by the combination of Flurbiprofen and Ofloxacin. Bacterial infection [1A00-1C4Z] [26]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Kanamycin. Bacterial infection [1A00-1C4Z] [27]
Sparfloxacin DMB4HCT Moderate Additive CNS depression effects by the combination of Flurbiprofen and Sparfloxacin. Bacterial infection [1A00-1C4Z] [26]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Streptomycin. Bacterial infection [1A00-1C4Z] [27]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Flurbiprofen and Gemifloxacin. Bacterial infection [1A00-1C4Z] [26]
Norfloxacin DMIZ6W2 Moderate Additive CNS depression effects by the combination of Flurbiprofen and Norfloxacin. Bacterial infection [1A00-1C4Z] [26]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Flurbiprofen and ABT-492. Bacterial infection [1A00-1C4Z] [26]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Gentamicin. Bacterial infection [1A00-1C4Z] [27]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Netilmicin. Bacterial infection [1A00-1C4Z] [27]
Levofloxacin DMS60RB Moderate Additive CNS depression effects by the combination of Flurbiprofen and Levofloxacin. Bacterial infection [1A00-1C4Z] [26]
Lomefloxacin DMVRH9C Moderate Additive CNS depression effects by the combination of Flurbiprofen and Lomefloxacin. Bacterial infection [1A00-1C4Z] [26]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Etidronic acid. Bone paget disease [FB85] [28]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Risedronate. Bone paget disease [FB85] [28]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [29]
Alpelisib DMEXMYK Moderate Increased metabolism of Flurbiprofen caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [30]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Flurbiprofen and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [25]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Iodipamide. Cholelithiasis [DC11] [31]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Levomilnacipran. Chronic pain [MG30] [32]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Flurbiprofen and Anisindione. Coagulation defect [3B10] [25]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Flurbiprofen and Regorafenib. Colorectal cancer [2B91] [24]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Methoxyflurane. Corneal disease [9A76-9A78] [24]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Flurbiprofen and Ardeparin. Coronary thrombosis [BA43] [33]
Mifepristone DMGZQEF Moderate Decreased metabolism of Flurbiprofen caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [34]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Flurbiprofen caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [35]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Flurbiprofen caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [36]
MK-8228 DMOB58Q Moderate Increased metabolism of Flurbiprofen caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [37]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Flurbiprofen and Danaparoid. Deep vein thrombosis [BD71] [33]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Flurbiprofen and Rivaroxaban. Deep vein thrombosis [BD71] [38]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Flurbiprofen and Sertraline. Depression [6A70-6A7Z] [32]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Flurbiprofen and Vilazodone. Depression [6A70-6A7Z] [32]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Flurbiprofen and Paroxetine. Depression [6A70-6A7Z] [32]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Flurbiprofen and Vortioxetine. Depression [6A70-6A7Z] [32]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Milnacipran. Depression [6A70-6A7Z] [32]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Flurbiprofen and Escitalopram. Depression [6A70-6A7Z] [32]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Flurbiprofen and Desvenlafaxine. Depression [6A70-6A7Z] [32]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Flurbiprofen and Clomipramine. Depression [6A70-6A7Z] [32]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Flurbiprofen and PMID28870136-Compound-49. Discovery agent [N.A.] [39]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Cannabidiol. Epileptic encephalopathy [8A62] [24]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Flurbiprofen when combined with Ethacrynic acid. Essential hypertension [BA00] [40]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Flurbiprofen and Tazemetostat. Follicular lymphoma [2A80] [25]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Flurbiprofen and Avapritinib. Gastrointestinal stromal tumour [2B5B] [24]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Sulfinpyrazone. Gout [FA25] [25]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Flurbiprofen when combined with Bumetanide. Heart failure [BD10-BD1Z] [40]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Flurbiprofen when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [40]
Rifapentine DMCHV4I Moderate Increased metabolism of Flurbiprofen caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [41]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Brentuximab vedotin. Hodgkin lymphoma [2B30] [42]
Etravirine DMGV8QU Moderate Decreased metabolism of Flurbiprofen caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and Mipomersen. Hyper-lipoproteinaemia [5C80] [44]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and Teriflunomide. Hyper-lipoproteinaemia [5C80] [21]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Flurbiprofen and BMS-201038. Hyper-lipoproteinaemia [5C80] [45]
Indapamide DMGN1PW Moderate Antagonize the effect of Flurbiprofen when combined with Indapamide. Hypertension [BA00-BA04] [40]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Flurbiprofen when combined with Trichlormethiazide. Hypertension [BA00-BA04] [40]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Flurbiprofen when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [40]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Flurbiprofen and Dipyridamole. Hypertension [BA00-BA04] [25]
Potassium chloride DMMTAJC Moderate Increased risk of hyperkalemia by the combination of Flurbiprofen and Potassium chloride. Hypo-kalaemia [5C77] [46]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Balsalazide. Indeterminate colitis [DD72] [19]
PF-06463922 DMKM7EW Moderate Increased metabolism of Flurbiprofen caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [22]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Flurbiprofen and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [47]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Idelalisib. Mature B-cell leukaemia [2A82] [48]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Flurbiprofen and Acalabrutinib. Mature B-cell lymphoma [2A85] [49]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Flurbiprofen and Ibrutinib. Mature B-cell lymphoma [2A85] [50]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Flurbiprofen and Ponatinib. Mature B-cell lymphoma [2A85] [51]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Flurbiprofen caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [24]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Exjade. Mineral absorption/transport disorder [5C64] [52]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Flurbiprofen and Panobinostat. Multiple myeloma [2A83] [22]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Deflazacort. Muscular dystrophy [8C70] [20]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Flurbiprofen and Ruxolitinib. Myeloproliferative neoplasm [2A20] [25]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Flurbiprofen and Dasatinib. Myeloproliferative neoplasm [2A20] [53]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Flurbiprofen and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [54]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Flurbiprofen and Prasugrel. Myocardial infarction [BA41-BA43] [24]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Flurbiprofen and Vorapaxar. Myocardial infarction [BA41-BA43] [55]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Flurbiprofen and Tirofiban. Myocardial infarction [BA41-BA43] [56]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Flurbiprofen and Sibutramine. Obesity [5B80-5B81] [32]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Flurbiprofen and Dexfenfluramine. Obesity [5B80-5B81] [32]
Polythiazide DMCH80F Moderate Antagonize the effect of Flurbiprofen when combined with Polythiazide. Oedema [MG29] [40]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Flurbiprofen caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [57]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Flurbiprofen and MK-4827. Ovarian cancer [2C73] [24]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Aspirin. Pain [MG30-MG3Z] [58]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Hydrocortisone. Postoperative inflammation [1A00-CA43] [20]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Epoprostenol. Pulmonary hypertension [BB01] [59]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Flurbiprofen and Iloprost. Pulmonary hypertension [BB01] [59]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Everolimus. Renal cell carcinoma [2C90] [60]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Temsirolimus. Renal cell carcinoma [2C90] [60]
Gatifloxacin DMSL679 Moderate Additive CNS depression effects by the combination of Flurbiprofen and Gatifloxacin. Respiratory infection [CA07-CA4Z] [26]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [20]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Flurbiprofen and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [24]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [20]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Flurbiprofen and Pitolisant. Somnolence [MG42] [24]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Flurbiprofen and Plicamycin. Testicular cancer [2C80] [25]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Caplacizumab. Thrombocytopenia [3B64] [25]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Flurbiprofen and Apixaban. Thrombosis [DB61-GB90] [24]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Flurbiprofen and Cangrelor. Thrombosis [DB61-GB90] [25]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Flurbiprofen and Brilinta. Thrombosis [DB61-GB90] [24]
Clopidogrel DMOL54H Moderate Increased risk of bleeding by the combination of Flurbiprofen and Clopidogrel. Thrombosis [DB61-GB90] [25]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Flurbiprofen and Cabozantinib. Thyroid cancer [2D10] [61]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Sirolimus. Transplant rejection [NE84] [60]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Flurbiprofen and Tacrolimus. Transplant rejection [NE84] [60]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Flurbiprofen and Tolbutamide. Type 2 diabetes mellitus [5A11] [23]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Olsalazine. Ulcerative colitis [DD71] [19]
Cinoxacin DM4EWNS Moderate Additive CNS depression effects by the combination of Flurbiprofen and Cinoxacin. Urinary tract infection [GC08] [26]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Flurbiprofen and Plazomicin. Urinary tract infection [GC08] [27]
Nalidixic acid DMRM0JV Moderate Additive CNS depression effects by the combination of Flurbiprofen and Nalidixic acid. Urinary tract infection [GC08] [26]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Flurbiprofen and Betrixaban. Venous thromboembolism [BD72] [62]
⏷ Show the Full List of 112 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 1 E00263 19700 Colorant
Hydrochloric acid E00015 313 Acidulant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Potassium chloride E00074 4873 Tonicity agent
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Edetate disodium E00186 8759 Complexing agent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 22 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Flurbiprofen 100 mg tablet 100 mg Oral Tablet Oral
Flurbiprofen 50 mg tablet 50 mg Oral Tablet Oral
Flurbiprofen Sodium 0.03% solution 0.03% Solution Ophthalmic
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Flurbiprofen FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4194).
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
8 Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm. 2015;41(8):1363-7.
9 Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos. 2007 Jul;35(7):1182-7.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys. 2009 Jul 15;487(2):139-45. doi: 10.1016/j.abb.2009.05.017. Epub 2009 Jun 6.
12 Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study. J Pharmacokinet Biopharm. 1997 Feb;25(1):63-77. doi: 10.1023/a:1025719827072.
13 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
14 In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents. Pharmacol Res. 2007 Apr;55(4):318-28.
15 Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen. Oncogene. 2001 Oct 18;20(47):6864-70.
16 Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41.
17 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
18 The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells. Cancer Res. 2007 Dec 1;67(23):11402-10. doi: 10.1158/0008-5472.CAN-07-1792.
19 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
20 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
21 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
22 Cerner Multum, Inc. "Australian Product Information.".
23 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
24 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
26 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
27 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
28 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
29 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
30 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
31 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
32 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
33 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
34 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
35 Cerner Multum, Inc. "Canadian Product Information.".
36 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
37 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
38 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
39 Canadian Pharmacists Association.
40 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
41 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
42 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
43 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
44 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
45 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
46 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
47 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
48 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
49 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
50 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
51 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
52 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
53 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
54 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
55 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
56 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
57 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
58 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
59 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
60 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
61 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
62 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.